Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Bristol-Myers Squibb
Seagen Inc.
Janssen Research & Development, LLC
Janssen Scientific Affairs, LLC
Janssen Research & Development, LLC
Merus B.V.
Catalyst Pharmaceuticals, Inc.
Amgen
TerSera Therapeutics LLC
Janssen Biotech, Inc.
Eli Lilly and Company
Eli Lilly and Company
Stanford University
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Servier
Day One Biopharmaceuticals, Inc.
University of California, Irvine
Gilead Sciences
Genmab
Takeda
Genentech, Inc.
argenx
Lahey Clinic
Aadi Bioscience, Inc.
OHSU Knight Cancer Institute
Yuhan Corporation
Bristol-Myers Squibb
Gilead Sciences
University of Colorado, Denver
Gilead Sciences
Jazz Pharmaceuticals
Jonsson Comprehensive Cancer Center
Astellas Pharma Inc
G1 Therapeutics, Inc.
University of California, San Francisco
Curium US LLC
MorphoSys AG
Blueprint Medicines Corporation
AstraZeneca
The Catholic University of Korea
Jazz Pharmaceuticals
Deciphera Pharmaceuticals, LLC
University of California, San Francisco